A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.Adam Sharp, Hendrik‐Tobias Arkenau, Anja Williams et al.|Journal of Clinical Oncology|2022Cited by 12
PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCLAdam Sharp, Hendrick-Tobias Arkenau, A. Williams et al.|HemaSphere|2022Cited by 5
NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Combination With Anti-PD-1 Therapy: A Phase I StudyColette J. Shen, Tanguy Y. Seiwert, Alexander T. Pearson et al.|International Journal of Radiation Oncology*Biology*Physics|2020Cited by 4
NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I TrialColette J. Shen, Tanguy Y. Seiwert, Jessica M. Frakes et al.|International Journal of Radiation Oncology*Biology*Physics|2021Cited by 1